Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

The PTAB, pharmaceutical patents and reverse payments

PTAB icon 165

The authors of a new white paper believe that almost 75% of pharmaceutical patent settlements at the Patent Trial and Appeal Board meet the criterion for inferring a strong likelihood of reverse payment settlement. The paper also suggests a rule to deter attempts to exploit the Board as a holdup device as well as discussing reverse patent trolls

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
more from across site and ros bottom lb

More from across our site

A Foss Patents blog post revealed that Mr Justice Marcus Smith handed down his judgment in Optis v Apple on May 10
Witnesses during a committee hearing criticised proposals to increase some fees by as much as 400%
Sources say they are likely to hire external counsel that can create a lasting first impression but will likely turn their backs on lawyers who have nothing new to offer
Varuni Paranavitane, of counsel at Finnegan, examines recent decisions by US and UK courts to demonstrate the proof of infringement that was required
The Federal Circuit will also narrow its investigation into Judge Newman to focus on whether her failure to cooperate constitutes misconduct
The management board will send three names to the Council of the EU for a final decision
Sources say a decision by the IP High Court will make it easier for rights owners to fight infringement
Seán Kelly asked the European Commission how it intends to ensure the EUIPO executive director vote, due tomorrow, will be fair and transparent
Counsel from BMW and Finnegan explain how they got an NPE to sign a covenant agreeing not to sue the automaker ever again
The blue checkmark could be a good tool, but it’s unclear how widespread its adoption will be, say in-house sources